Maxime Huerre

Sleep is one of healthcare’s biggest blind spots. Access is slow, confusing and uneven, and millions of people who need help never get it. Sunrise exists to change that. Born from pioneering research on mandibular jaw movement, we built a chin-based sleep test that reinvented how sleep disorders can be diagnosed from home. That breakthrough has evolved into a full sleep-health platform: advanced diagnostic and treatment technology paired with clinical care delivered directly to patients’ homes through Dreem Health in all 50 U.S. states. Across the U.S. and Europe, our 100+ clinicians, engineers and operators share one mission: make high-quality sleep care accessible to everyone. Backed by more than $50M, we’re taking on one of healthcare’s biggest challenges: the 1+ billion people worldwide who still can’t get the sleep care they need.

Theremia is a pioneering health tech company focused on transforming drug development through advanced AI technologies. We specialize in optimizing drug derivatives for specific population subgroups, with a focus on neurological disorders. Our platform aims to improve treatment efficacy and reduce side effects, ultimately providing more personalized and effective healthcare solutions. At Theremia, we work at the intersection of AI, data science, and pharma to create groundbreaking innovations in medicine. Our mission is to help pharmaceutical companies unlock the full potential of their treatments by identifying and targeting diverse patient needs. Interested in collaborating or testing our pilot program? Contact us at: contact@theremia.health

May accompagne les (futurs) parents au quotidien dans lincroyable aventure de la parentalité.

Surge develops PreCyte, an immune-based diagnostic approach to identify patients at risk of postoperative complications and support smarter discharge and care pathways. PreCyte focuses on immune signatures associated with surgical site infection and pulmonary complications, helping care teams intervene earlier and allocate resources more effectively. Use cases - Postoperative risk stratification for surgical site infection and pulmonary complications - Support for discharge timing and pathway optimization in perioperative care - Immune profiling to inform patient monitoring and follow-up decisions Proof points - Early clinical deployments with leading academic medical centers - Built on more than a decade of translational immunology and multi-omics research - Developed with a strong focus on quality, clinical proofpoints, and technological breakthroughs

LegalPlace est la LegalTech française de référence pour créer et gérer son entreprise en ligne, simplement. Depuis 2016, nous accompagnons les entrepreneurs à chaque étape de leur aventure : - création d’entreprise (rédaction et dépôt de statuts, immatriculation, obtention du Kbis) - domiciliation et dépôt de capital - formalités juridiques au fil de la vie de l’entreprise -comptabilité digitalisée et gestion administrative au quotidien Notre force ? Une technologie propriétaire qui automatise les démarches, combinée à l’expertise de nos équipes internes de juristes, d’experts-comptables et d’ingénieurs. Résultat : un service en ligne fiable, rapide et sécurisé, pensé pour faire gagner du temps et enlever la complexité aux entrepreneurs. Certifiée Qualiopi et Activateur France Num, LegalPlace s’engage à simplifier durablement la création et la gestion d’entreprise pour permettre à chacun d’entreprendre avec sérénité. 👉 Notre mission : rendre l’entrepreneuriat accessible à tous, en transformant les formalités en une expérience claire, digitale et humaine.

Eurazeo is a leading global investment company, with a diversified portfolio of €39 billion in assets under management, including €30 billion from third parties, invested in 600 companies. With its considerable private equity, private debt as well as real estate and infrastructure asset expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its nearly 450 professionals and by offering deep sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term. Eurazeo has offices in Paris, New York, London, Frankfurt, Berlin, Milan, Madrid, Luxembourg, Shanghai, Seoul, Singapore, Stockholm, Sao Paulo and Tokyo. Eurazeo is listed on Euronext Paris. *** Eurazeo est un groupe dinvestissement mondial de premier plan, qui gère 39 milliards d’euros d’actifs diversifiés dont 30 milliards pour compte de tiers investis dans un portefeuille de 600 entreprises. Fort de son expertise dans le Private Equity, la dette privée et les actifs immobiliers et infrastructures, le groupe accompagne les entreprises de toute taille, mettant au service de leur développement l’engagement de ses près de 450 collaborateurs, sa profonde expertise sectorielle, son accès privilégié aux marchés mondiaux, ainsi que son approche responsable de la création de valeur fondée sur la croissance. Son actionnariat institutionnel et familial, sa structure financière solide sans endettement structurel et son horizon d’investissement flexible lui permettent d’accompagner les entreprises dans la durée. Eurazeo dispose de bureaux à Paris, New York, Londres, Francfort, Berlin, Milan, Madrid, Luxembourg, Shanghai, Séoul, Singapour, Stockholm, Sao Paulo et Tokyo. Eurazeo est cotée sur Euronext Paris.

Sleep is one of healthcare’s biggest blind spots. Access is slow, confusing and uneven, and millions of people who need help never get it. Sunrise exists to change that. Born from pioneering research on mandibular jaw movement, we built a chin-based sleep test that reinvented how sleep disorders can be diagnosed from home. That breakthrough has evolved into a full sleep-health platform: advanced diagnostic and treatment technology paired with clinical care delivered directly to patients’ homes through Dreem Health in all 50 U.S. states. Across the U.S. and Europe, our 100+ clinicians, engineers and operators share one mission: make high-quality sleep care accessible to everyone. Backed by more than $50M, we’re taking on one of healthcare’s biggest challenges: the 1+ billion people worldwide who still can’t get the sleep care they need.

Theremia is a pioneering health tech company focused on transforming drug development through advanced AI technologies. We specialize in optimizing drug derivatives for specific population subgroups, with a focus on neurological disorders. Our platform aims to improve treatment efficacy and reduce side effects, ultimately providing more personalized and effective healthcare solutions. At Theremia, we work at the intersection of AI, data science, and pharma to create groundbreaking innovations in medicine. Our mission is to help pharmaceutical companies unlock the full potential of their treatments by identifying and targeting diverse patient needs. Interested in collaborating or testing our pilot program? Contact us at: contact@theremia.health

May accompagne les (futurs) parents au quotidien dans lincroyable aventure de la parentalité.

Surge develops PreCyte, an immune-based diagnostic approach to identify patients at risk of postoperative complications and support smarter discharge and care pathways. PreCyte focuses on immune signatures associated with surgical site infection and pulmonary complications, helping care teams intervene earlier and allocate resources more effectively. Use cases - Postoperative risk stratification for surgical site infection and pulmonary complications - Support for discharge timing and pathway optimization in perioperative care - Immune profiling to inform patient monitoring and follow-up decisions Proof points - Early clinical deployments with leading academic medical centers - Built on more than a decade of translational immunology and multi-omics research - Developed with a strong focus on quality, clinical proofpoints, and technological breakthroughs

Were hiring worldwide! https://wandercraft.welcomekit.co/ At Wandercraft, we believe movement is freedom. Since 2012, our mission has been simple but bold: restore mobility where it’s been lost, and expand what’s possible with robotics that move like people do. We see robotics as the ultimate partners—machines that can do what humans cannot, or should not, do. That means giving back the ability to walk to someone with a spinal cord injury, or stepping in on a factory floor where work is too heavy, repetitive, or hazardous. We pioneered the world’s first self-balancing exoskeleton—technology that doesn’t rely on crutches or walkers, but lets people stand and walk freely. Today, our work goes beyond healthcare. From rehabilitation centers to factory floors, and soon into homes and communities, we’re shaping a future where humans and robots move forward together. Our technology, powered by physical AI and 30+ patents, is life-tested in the most demanding environments: real people, real steps, real work. Meet our devices: Atalante X – A self-balancing exoskeleton enabling hundreds of patients with mobility disabilities to take over 1 million steps per month in 100+ leading hospitals and research centers worldwide. It is designed to promote upright posture, cardiovascular health, neuroplasticity, and—most importantly—upright independence. Eve – The world’s first self-balancing exoskeleton for personal use. Designed for daily life, Eve enables individuals with severe mobility impairments to walk hands-free at home and outdoors. Currently in U.S. clinical trials, Eve is expected to launch in 2026. Calvin-40 – Our first industrial humanoid robot. Autonomous and voice-operated, Calvin-40 is built to take on physically demanding or hazardous tasks in non-ergonomic environments. Based on the same platform as our exoskeletons, Calvin is already hard at work with Renault Group and more.